ArticlePLoS pathogens2026
Engineered Lactobacillus paracasei 3×pBD1/ΔHLJ-27 as a novel antibiotic alternative for livestock: Dual efficacy in growth promotion and protection against Salmonella infection via integrated host-microbiota-immune regulation.
Article in PLoS pathogens, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
To address the antimicrobial resistance (AMR) crisis driven by livestock agriculture, effective antibiotic alternatives are urgently needed. However, current probiotic and antimicrobial peptide strategies are critically hindered by limited efficacy, poor stability, and a lack of systemic protection. This study employed recombinant Lactobacillus paracasei 3 × pBD1/ΔHLJ-27, which can secrete and express multicopy porcine β-defensin-1 (pBD1), a cationic antimicrobial peptide with broad-spectrum activity. The study demonstrate that this engineered strain confers systemic protection against Salmonella Typhimurium (S. Typhimurium) infection by coordinately enhancing intestinal barrier integrity and modulating host immune responses. Specifically, 3 × pBD1/ΔHLJ-27 improved intestinal morphology and upregulated tight junction proteins, while promoting balanced immune activation characterized by increased CD4 ⁺ T cells and elevated SIgA and IgG levels. In infection models, the strain significantly reduced mortality, limited bacterial dissemination, and alleviated intestinal pathology. Mechanistically, these protective effects are associated with suppression of excessive inflammatory responses and reprogramming of host-microbiota interactions, as evidenced by reduced pro-inflammatory signaling and enrichment of beneficial microbial taxa. Collectively, these findings identify 3 × pBD1/ΔHLJ-27 as a multifunctional engineered probiotic that integrates antimicrobial activity with immune regulation, offering a promising and scalable alternative to antibiotics in animal production.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.